Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 4
2008 4
2009 3
2010 1
2011 3
2012 4
2013 2
2014 2
2015 3
2016 1
2017 5
2018 3
2019 3
2020 3
2021 1
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, Martín-Martín N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazón A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH. Araujo AM, et al. Among authors: urruticoechea a. J Clin Invest. 2022 Apr 1;132(7):e148667. doi: 10.1172/JCI148667. J Clin Invest. 2022. PMID: 35192545 Free PMC article.
Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.
Sánchez-Magraner L, Gumuzio J, Miles J, Quimi N, Martínez Del Prado P, Abad-Villar MT, Pikabea F, Ortega L, Etxezarraga C, Martín-Algarra S, Lozano MD, Saiz-Camin M, Egurrola-Izquierdo M, Barredo-Santamaría I, Saiz-López A, Gomez-Mediavilla J, Segues-Merino N, Juaristi-Abaunz MA, Urruticoechea A, Geraedts EJ, van Elst K, Claessens NJM, Italiano A, Applebee CJ, Del Castillo S, Evans C, Aguirre F, Parker PJ, Calleja V. Sánchez-Magraner L, et al. Among authors: urruticoechea a. J Clin Oncol. 2023 May 10;41(14):2561-2570. doi: 10.1200/JCO.22.01748. Epub 2023 Feb 23. J Clin Oncol. 2023. PMID: 36821809 Free PMC article.
Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study.
Hiensch AE, Monninkhof EM, Schmidt ME, Zopf EM, Bolam KA, Aaronson NK, Belloso J, Bloch W, Clauss D, Depenbusch J, Lachowicz M, Pelaez M, Rundqvist H, Senkus E, Stuiver MM, Trevaskis M, Urruticoechea A, Rosenberger F, van der Wall E, de Wit GA, Zimmer P, Wengström Y, Steindorf K, May AM. Hiensch AE, et al. Among authors: urruticoechea a. Trials. 2022 Jul 29;23(1):610. doi: 10.1186/s13063-022-06556-7. Trials. 2022. PMID: 35906659 Free PMC article. Clinical Trial.
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, Martín-Martín N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazón A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH. Araujo AM, et al. Among authors: urruticoechea a. J Clin Invest. 2022 Oct 3;132(19):e165107. doi: 10.1172/JCI165107. J Clin Invest. 2022. PMID: 36169029 Free PMC article. No abstract available.
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, Fernández-García P, Lladó V, McNicholl AG, Rosselló CA, Taylor RJ, Azaro A, Rodón J, Sludden J, Veal GJ, Plummer R, Urruticoechea A, Lahuerta A, Mujika K, Escribá PV. Lopez J, et al. Among authors: urruticoechea a. Br J Cancer. 2023 Sep;129(5):811-818. doi: 10.1038/s41416-023-02356-1. Epub 2023 Jul 24. Br J Cancer. 2023. PMID: 37488446 Free PMC article. Clinical Trial.
Proliferation marker Ki-67 in early breast cancer.
Urruticoechea A, Smith IE, Dowsett M. Urruticoechea A, et al. J Clin Oncol. 2005 Oct 1;23(28):7212-20. doi: 10.1200/JCO.2005.07.501. J Clin Oncol. 2005. PMID: 16192605 Review.
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer.
Bacci M, Lorito N, Smiriglia A, Subbiani A, Bonechi F, Comito G, Morriset L, El Botty R, Benelli M, López-Velazco JI, Caffarel MM, Urruticoechea A, Sflomos G, Malorni L, Corsini M, Ippolito L, Giannoni E, Meattini I, Matafora V, Havas K, Bachi A, Chiarugi P, Marangoni E, Morandi A. Bacci M, et al. Among authors: urruticoechea a. Sci Transl Med. 2024 Feb 28;16(736):eadf9874. doi: 10.1126/scitranslmed.adf9874. Epub 2024 Feb 28. Sci Transl Med. 2024. PMID: 38416843
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
López-Velazco JI, Manzano S, Otaño M, Elorriaga K, Bultó N, Herrero J, Lahuerta A, Segur V, Álvarez-López I, Caffarel MM, Urruticoechea A. López-Velazco JI, et al. Among authors: urruticoechea a. Breast Cancer Res. 2024 Jan 3;26(1):3. doi: 10.1186/s13058-023-01756-8. Breast Cancer Res. 2024. PMID: 38173005 Free PMC article.
Eribulin mesylate in breast cancer.
Verdaguer H, Morilla I, Urruticoechea A. Verdaguer H, et al. Among authors: urruticoechea a. Womens Health (Lond). 2013 Nov;9(6):517-26. doi: 10.2217/whe.13.61. Womens Health (Lond). 2013. PMID: 24161305 Free article.
47 results